Non-red blood cell transfusion as a risk factor for mortality following percutaneous coronary intervention

• Published in: International journal of cardiology Vol. 157; no. 2; pp. 169 - 173
• Main Authors: Robinson, Simon D., Janssen, Christian, Fretz, Eric B., Chase, Alex J., Siega, Anthony Della, Carere, Ronald G., Fung, Anthony, Simkus, Gerald, Hilton, J. David, Berry, Brian, Klinke, W. Peter
• Format: Journal Article
• Language: English
• Published: Shannon Elsevier Ireland Ltd 31.05.2012; Elsevier
• Subjects: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary - adverse effects; Angioplasty, Balloon, Coronary - mortality; Biological and medical sciences; Cardiology. Vascular system; Cardiovascular; Contraindications; Diseases of the cardiovascular system; Erythrocyte Transfusion - adverse effects; Erythrocyte Transfusion - mortality; Female; Hemorrhage - etiology; Hemorrhage - mortality; Humans; Male; Medical sciences; Middle Aged; Mortality; Percutaneous coronary intervention; Plasma; Platelet Transfusion - adverse effects; Platelet Transfusion - mortality; Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects); Risk Factors; Survival Rate - trends; Transfusion; Mortality; Percutaneous coronary intervention; Transfusion; Atherectomy; Prognosis; Angioplasty; Coronary artery; Red blood cell; Instrumentation therapy; Stent; Percutaneous route; Risk factor; Cardiology
• ISSN: 0167-5273; 1874-1754; 1874-1754
• DOI: 10.1016/j.ijcard.2010.12.013

Bleeding following percutaneous coronary intervention (PCI) is common and may lead to transfusion and death. Although previous work has examined the effect of red blood cell (RBC) transfusion in patients with coronary disease, no study had investigated whether transfusion of non-RBC components was associated with mortality following PCI. All subjects transfused in the 10days following PCI were identified using the British Columbia Cardiac and Central Transfusion Registries. Patients undergoing cardiac surgery following PCI were excluded as transfusion was assumed to be due to surgical related bleeding. Transfusion products were categorised as RBC and non-RBC comprising platelets, plasma and cryoprecipitate. Blood product use was compared according to thirty day mortality using multivariate regression and propensity adjustment for confounding variables. From a total of 32,580 patients who underwent PCI, 952 patients received at least 1 blood product within 10days of PCI. Non-RBC transfusion occurred more commonly in the cohort of transfused patients dying within 30days (p<0.001). After adjustment for baseline risk, transfusion of plasma/cryoprecipitate (HR 5.17; 95% C.I. 2.87–9.32, p<0.001) and platelets (HR 2.13; 95% C.I. 1.10–4.13, p=0.03) was associated with increased 30day mortality. In a propensity risk adjusted model, transfusion of plasma/cryoprecipitate and RBC transfusion volume remained as significant predictors of 30-day mortality (p<0.001). Transfusion following PCI appears to be associated with an increased risk of death within 30days. We now report that transfusion with plasma rich non-RBC products may confer an additional mortality risk to patients undergoing PCI.